NCT04523857 2025-04-04
ABBY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
Clinical Trials
10 trialsNCT04841148 2025-03-11
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06328387 2024-03-25
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT05689359 2024-03-08
Evaluation of Hydroxychloroquine to Prevent CIPN
University of Arizona
Phase 2 Withdrawn
NCT00765765 2023-08-09
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT04316169 2022-12-23
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Phase 1 Withdrawn
NCT03400254 2020-04-28
GLACIER
Abramson Cancer Center at Penn Medicine
Phase 1/2 Withdrawn
NCT02414776 2017-09-27
ABC01
Western Regional Medical Center
Phase 1 Terminated
NCT01292408 2012-01-20
Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients
Radboud University Medical Center
Phase 2 Unknown